Currently, 1p/19q status often informs adjuvant treatment regimen choice in grade 3 IDH-mutant gliomas, with 1p/19q codeleted patients receiving RT + PCV and 1p/19q noncodeleted patients receiving RT + TMZ6,18,24–26. This evidence concerns the gene IDH1 and glioma.